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Abstract
Background: A number of studies assessed the association of 2675 4G/5G polymorphism in the promoter region of
plasminogen activator inhibitor (PAI)-1 gene with asthma in different populations. However, most studies reported
inconclusive results. A meta-analysis was conducted to investigate the association between polymorphism in the PAI-1 gene
and asthma susceptibility.
Methods: Databases including Pubmed, EMBASE, HuGE Literature Finder, Wanfang Database, China National Knowledge
Infrastructure (CNKI) and Weipu Database were searched to find relevant studies. Odds ratios (ORs) with 95% confidence
intervals (CIs) were used to assess the strength of association in the dominant model, recessive model, codominant model,
and additive model.
Results: Eight studies involving 1817 cases and 2327 controls were included. Overall, significant association between 4G/5G
polymorphism and asthma susceptibility was observed for 4G4G+4G5G vs. 5G5G (OR=1.56, 95% CI 1.12–2.18, P=0.008),
4G/4G vs. 4G/5G+5G/5G (OR=1.38, 95% CI 1.06–1.80, P=0.02), 4G/4G vs. 5G/5G (OR=1.80, 95% CI 1.17–2.76, P=0.007), 4G/
5G vs. 5G/5G (OR=1.40, 95% CI 1.07–1.84, P=0.02), and 4G vs. 5G (OR=1.35, 95% CI 1.08–1.68, P=0.008).
Conclusions: This meta-analysis suggested that the 2675 4G/5G polymorphism of PAI-1 gene was a risk factor of asthma.
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Introduction
Asthma is one of the most common chronic diseases affecting an
estimated 300 million people worldwide [1]. Currently, it is
recognized that asthma is a complex disease that results from
interactions between multiple genetic and environmental factors
[2]. Numerous studies have focused on the association between
genetic variants and asthma risk, and the plasminogen activator
inhibitor (PAI)-1 gene has been extensively studied.
PAI-1, a key regulator of the fibrinolytic system, is involved in
various physiological functions and associated with many diseases.
Kelly et al. [3] reported that PAI-1 mRNA expression was up-
regulated in the bronchial wall at two weeks after chronic allergen
exposure in the asthmatic mice. In house dust mite-sensitive
allergic asthmatics, the average plasma level of PAI-1 was
49.7 ng/mL, and in healthy controls it was only 26.0 ng/mL
(P,0.0001) [4]. Taken together, these facts suggested that PAI-1
may play an important role in pathogenesis of asthma.
The human PAI-1 gene is located on chromosome 7 (q21.3–
q22), where a locus related to serum IgE levels has been mapped
[5]. The 4G/5G polymorphism (dbSNP rs1799889), which is
characterized by a single guanosine nucleotide insertion/deletion
variation at 2675 bp of the PAI-1 promoter, has been identified.
The 4G/5G polymorphism is a major genetic determinant of
plasma PAI-1 levels [6] and has been studied as a potential
susceptibility factor for asthma. Several studies reported the
association between the 4G/5G polymorphism of PAI-1 gene and
the risk of asthma [7–14], but the results were inconclusive.
Considering a single study may lack the power to provide
reliable conclusion, we performed a meta-analysis to investigate
the precise relationship between the PAI-1 gene variants and
asthma. This was, to our knowledge, the first meta-analysis of the
association between PAI-1 polymorphism and asthma susceptibil-
ity.
Methods
Publication search
Pubmed, EMBASE, HuGE Literature Finder, Wanfang
Database, China National Knowledge Infrastructure (CNKI)
and Weipu Database were all searched (Last search was updated
on October, 2011). The following terms were used in searching:
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e34385(asthma or asthmatic) and (plasminogen activator inhibitor-1 or
PAI-1 or SERPINE1) and (polymorphism or mutation or variant).
No publication date or language restrictions were imposed. All the
searched studies were retrieved, and their references were checked
as well for other relevant publications. Review articles were also
searched to find additional eligible studies.
Inclusion and Exclusion Criteria
Studies fulfilling the following selection criteria were included in
this meta-analysis: (1) evaluation of the 4G/5G polymorphism in
PAI-1 gene and asthma risk, (2) using a case-control design, (3)
genotype distributions in both cases and controls should be
available for estimating an odds ratio (OR) with 95% confidence
interval (CI), and (4) genotype distribution of control group must
be consistent with Hardy–Weinberg equilibrium (HWE). Studies
were excluded if one of the following existed: (1) not relevant to
PAI-1 or asthma, (2) the design based on family or sibling pairs, (3)
genotype frequencies or number not reported, and (4) reviews and
abstracts. For overlapping studies, only the one with the largest
sample numbers was included.
Data Extraction
Two investigators (Nie and Li) independently reviewed full
manuscripts of eligible studies, and the relevant data were
extracted into predesigned data collection forms. We verified
accuracy of data by comparing collection forms from each
investigator. Any discrepancy was resolved by discussion or a
third author (Xiu) would assess these articles. The following
variables were collected from each study: first author’s name, year
of publication, original country, ethnicity, sample size, asthma
definition, genotyping method, atopic status, and genotype
numbers in cases and controls.
Statistical Analysis
The strength of the association between the 4G/5G polymor-
phism and asthma risk was measured by OR and 95% CI. The
statistical significance of OR was analyzed by Z test, and P,0.05
was considered as statistically significant. We first estimated with
the dominant model (4G4G+4G5G vs. 5G5G) and recessive
model (4G4G vs. 4G5G+5G5G) and then evaluated codominant
model (4G4G vs. 5G5G and 4G5G vs. 5G5G). We also estimated
the risks of additive model (4G vs. 5G).
The heterogeneity between the studies was assessed by the Chi
square-test based Cochrane Q-test. I
2 was also used to test the
heterogeneity among the included studies. A P value.0.10 for the
Q-test indicates a lack of heterogeneity among the studies, then the
pooled OR estimate of each study was calculated by the fixed-
effects model (the Mantel-Haenszel method). Otherwise, the
random-effects model (the DerSimonian and Laird method) was
used. In addition, a Chi square-test was used to determine if
observed frequency of genotype in control population conformed
to HWE expectations.
To evaluate the ethnic-specific, age-specific, and atopic-specific
effects and to explore sources of heterogeneity, subgroup analyses
were performed by ethnicity, age, and atopic status. Sensitivity
analysis was performed through sequentially excluded individual
studies to assess the stability of the results. Asymmetry funnel plots
were used to assess potential publication bias. The Begg’s test [15]
and Egger’s test [16] were also used to assess publication bias
statistically.
All statistical tests were performed by using the Revman 5.1
software (Nordic Cochrane Center, Copenhagen, Denmark) and
STATA 11.0 software (Stata Corporation, College Station, TX).
Results
Study Characteristics
Figure 1 outlines our study selection process. Briefly, a total of
466 articles were identified after an initial search. After removing
duplications and reading the abstracts, 430 articles were excluded
for not being relevant to asthma. One abstract was excluded
because we could not get the full text. After reading full texts of the
remaining 20 articles, twelve were then excluded and eight
remained. One article reported two cohorts [14], and each cohort
Figure 1. Flow of study identification, inclusion, and exclusion.
doi:10.1371/journal.pone.0034385.g001
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9 case-control studies in 8 articles were identified met our inclusion
criteria [7–14], including 1817 cases and 2327 controls. There
were 4 studies of Asians [9,11–13] and 4 studies of Caucasians
[7,8,10,14]. Four studies were performed in adults [10,12–14], one
in children [11], and three included both children and adults [7–
9]. Three studies only included atopic asthma patients [7,8,10],
two studies included both of these patients [9,12], and three studies
did not offer detailed information [11,13,14]. The characteristics
of each study included in this meta-analysis are presented in
Table S1. Genotype numbers and HWE examination results are
listed in Table S2.
Quantitative Data Synthesis
All studies. As shown in Figure 2, we analyzed the
heterogeneity of 4G4G+4G5G vs. 5G5G for all the 9 studies,
and the value of x
2 was 27.08 and P=0.0007 in a random effects
model. In addition, the I
2 value was 70%, suggesting significant
heterogeneity. Therefore, the random-effects model was used for
synthesis of the data. The overall OR for 4G4G+4G5G genotypes
versus 5G5G genotypes (dominant model) was 1.56 (95% CI 1.12–
2.18) and the Z test for overall effect was 2.65 (P=0.008). This
result suggested that individuals who carry the 4G allele may have
a 56% increased asthma risk compared with 5G5G homozygote.
When all the studies were pooled into meta-analysis using other
genetic models (Table S3), there was also significant association
between 4G/5G and asthma risk (for recessive model: OR=1.38,
95% CI 1.06–1.80, P=0.02; for codominant model: OR=1.80,
95% CI 1.17–2.76, P=0.007, and OR=1.40, 95% CI 1.07–1.84,
P=0.02; for addictive model: OR=1.35, 95% CI 1.08–1.68,
P=0.008).
Subgroup analyses. In the subgroup analyses by ethnicity,
significant associations were found among Asians (OR 1.40, 95%
CI 1.06–1.86, P=0.02) but not among Caucasians (OR 1.66, 95%
CI 0.97–2.86, P=0.07) in dominant model (4G4G+4G5G vs.
5G5G). Thus, Asian carriers of the 4G allele may have an
increased risk of asthma. In the subgroup analyses by age,
significant associations were found among adults (OR 1.61, 95%
CI 1.04–2.50, P=0.03), suggesting that adults carriers of 4G allele
may have a 61% increased risk of asthma. Subgroup analyses were
also performed by atopic status. Significant increased risk of
asthma was found among atopic asthma patients (OR 2.51, 95%
CI 1.81–3.46, P,0.00001). The result suggested that the 4G allele
carriers (4G4G+4G5G) have an increased risk of atopic asthma
compared with those individuals with the 5G5G homozygote.
Furthermore, the heterogeneity was decreased significantly in
atopic subgroup in every genetic model, suggesting atopic status
was the potentially important source of heterogeneity. Summary
results of other genetic comparisons are listed in Table S3.
Sensitivity Analysis. In order to assess the stability of the
results of the meta-analysis, we performed a sensitivity analysis
through sequentially excluded individual studies. Statistically
similar results were obtained after sequentially excluding each
study, suggesting stability of the meta-analyses.
Publication bias. Publication bias was assessed by Begg’s
funnel plot and Egger’s test. The shape of the funnel plot showed
slightly asymmetric in the 4G4G+4G5G vs. 5G5G comparison
genetic model, suggesting the possibility of publication bias
(Figure 3). Then, the Egger’s test was performed to provide
statistical evidence of funnel plot asymmetry. The results indicated
a lack of publication bias of the current meta-analysis (t=1.48,
P=0.182).
Discussion
Asthma is a genetically complex disease caused by multiple
genetic and environmental factors and is the result of the
interaction of multiple genetic and environmental factors [17].
The pathophysiologic hallmark of asthma is chronic inflammation
leading to airway hyper-responsiveness (AHR), mucous hyperse-
cretion and remodeling of airways [18]. Recent studies suggested
that PAI-1 may promote the development of asthma by facilitating
AHR, allergic inflammation, and airway remodeling [19]. For
instance, Savov et al. [20] reported that four weeks after
lipopolysaccharide inhalation, AHR and the expansion of the
subepithelial area in the medium and large airways were observed
in WT but not in PAI-1 deficient mice. In a murine allergic rhinitis
model, the immune response appeared to be a dominant Th2
response in WT mice; however, in PAI-1 deficient mice, the Th2
response was shifted to a Th1-dominant response, suggesting a key
role of PAI-1 in allergic inflammation [21]. In addition, PAI-1
promoted extracellular matrix (ECM) deposition in the asthmatic
airways. After OVA challenge, the levels of collagen deposition
were approximately 50% less in lung tissues from PAI-1 deficient
Figure 2. Meta-analysis with a random-effects model for the association between asthma risk and the PAI-1 4G/5G polymorphism
(4G4G+4G5G vs. 5G5G).
doi:10.1371/journal.pone.0034385.g002
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that PAI-1 may play an essential role in the pathogenesis of
asthma. Among SNPs of the PAI-1 gene, the 4G/5G polymor-
phism has been extensively studied. The 4G/4G genotype has
been linked to higher PAI-1 level, compared with the 5G/5G
genotype, with the heterozygous genotype associated with
intermediate levels [23]. It is biologically plausible that 4G/5G
polymorphism which affects PAI-1 level could influence the
susceptibility to asthma.
This current meta-analysis of 8 studies including 1817 cases and
2327 controls systematically evaluated the association between
2675 4G/5G polymorphism in the PAI-1 gene promoter and
asthma risk. The results indicated that 2675 4G/5G polymor-
phism was a conspicuous high risk factor for developing asthma in
the overall study populations. In the subgroup analysis by
ethnicity, no significant association was found in Caucasians in
dominant model. However, asthma risk was increased in Asians
(P=0.02), suggesting a possible influence among environmental
exposures and different genetic backgrounds. Cho et al. [24]
reported that the 4G allele of the PAI-1 gene may be associated
with the development of asthma in children. However, significant
associations were only found in adults (P=0.03). Since this meta-
analysis included only one study using children population, the
positive association between children and asthma could not be
ruled out because studies with small sample size may have
insufficient statistical power to detect a slight effect. Additional
future studies should be performed focusing on children with
asthma. Subgroup analysis was also performed among atopic
status patients. Significant increased risk of asthma was found in
these patients (P,0.00001), suggesting a possible role of PAI-1 in
the etiology of allergic asthma. In addition, all atopic status
patients were Caucasians. More studies are warranted to further
validate atopic status difference in the effect of this polymorphism
on asthma susceptibility, especially in Asians.
As the publication of findings often depends on the expectation
of researchers, false-negative results may be suppressed or false-
positive results magnified [25]. The results of this study, however,
did not show significant publication bias. However, since the
number of studies included in this meta-analysis was small and
large interstudy heterogeneity was observed. Significant heteroge-
neity existed in overall comparisons in each genetic model. The
observed heterogeneity could be attributable to differences in
several factors such as atopic status, ethnic variations, environ-
mental factors and methodological factors in design and conduct
of the studies. Among these factors, atopic status could play a
crucial role. After subgroup analysis by atopic status, the
heterogeneity was effectively decreased in atopic asthma patients.
Therefore, it can be presumed that the relatively large heteroge-
neity mainly results from differences of atopic status.
The present meta-analysis had several limitations that must be
taken into account. First, the number of available studies that
could be included in this meta-analysis was moderate. Therefore,
the results could be influenced by the factors like random error.
Second, the overall outcomes were based on individual unadjusted
ORs, while a more precise evaluation should be adjusted by other
potentially suspected factors including age, sex, and environmental
factors. Third, because of the complex nature of asthma, it is
unlikely that a SNP in one single gene would be obviously
associated with an increase in asthma risk, without consideration
of any other polymorphic susceptible genes. Kowal et al. [10]
pointed out that the synergistic interactions of the 4G/5G
polymorphism with the CD14 C-159T polymorphism affected
susceptibility and severity of house dust mite-allergic asthma.
Thus, we could not rule out the possibility of SNP–SNP
interactions. Fourth, there was no study of American African
population and only one study of children in this meta-analysis.
Finally, since the number of studies included in the subgroup
analyses was small, the results lacked sufficient reliability to
confirm or refute an association in a definitive manner.
To our knowledge, this study was the first comprehensive meta-
analysis to assess the relationship between the PAI-1 4G/5G
polymorphism and asthma susceptibility. It provided evidence of
the association between PAI-1 2675 4G/5G polymorphism and
asthma risk, supporting the hypothesis that the PAI-1 2675 4G/
Figure 3. Begg’s funnel plot for publication bias in selection of studies on the PAI-1 4G/5G polymorphism (4G4G+4G5G vs. 5G5G).
doi:10.1371/journal.pone.0034385.g003
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However, additional large case-control studies are required to
validate our findings. Future analyses should be conducted in
large-scale cohorts and should study the potential effect modifi-
cation by age and atopic status in different populations. Moreover,
gene-gene and gene-environment interactions should also be
considered in future studies.
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